Technical Analysis for CRDL - Cardiol Therapeutics Inc.

Grade Last Price % Change Price Change
C 2.17 -8.05% -0.19
CRDL closed down 8.05 percent on Friday, May 17, 2024, on 1.14 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Earnings Movers Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -8.05%
New 52 Week High Strength -8.05%

   Recent Intraday Alerts

Alert Time
Down 5% 1 day ago
Down 3% 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cardiol Therapeutics Inc. Description

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Disease Clinical Research Heart Failure Orphan Drug Heart Disease Cannabidiol

Is CRDL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.41
52 Week Low 0.5902
Average Volume 303,394
200-Day Moving Average 1.22
50-Day Moving Average 1.83
20-Day Moving Average 2.02
10-Day Moving Average 2.16
Average True Range 0.15
RSI (14) 57.98
ADX 32.83
+DI 25.73
-DI 15.90
Chandelier Exit (Long, 3 ATRs) 1.95
Chandelier Exit (Short, 3 ATRs) 2.01
Upper Bollinger Bands 2.38
Lower Bollinger Band 1.66
Percent B (%b) 0.71
BandWidth 35.77
MACD Line 0.13
MACD Signal Line 0.11
MACD Histogram 0.0201
Fundamentals Value
Market Cap 141.3 Million
Num Shares 65.1 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -6.78
Price-to-Sales 1069.35
Price-to-Book 2.71
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.58
Resistance 3 (R3) 2.61 2.50 2.51
Resistance 2 (R2) 2.50 2.40 2.49 2.48
Resistance 1 (R1) 2.34 2.34 2.29 2.31 2.46
Pivot Point 2.23 2.23 2.21 2.22 2.23
Support 1 (S1) 2.07 2.13 2.02 2.04 1.88
Support 2 (S2) 1.96 2.07 1.95 1.86
Support 3 (S3) 1.80 1.96 1.83
Support 4 (S4) 1.77